Evommune (EVMN) Other Working Capital Changes (2025)

Evommune (EVMN) has reported Other Working Capital Changes for 3 consecutive years, with -$193000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Working Capital Changes rose 6.31% year-over-year to -$193000.0; the TTM figure through Mar 2026 stood at -$3.0 million (changed N/A YoY), while the FY2025 annual figure was -$3.0 million, down 290.12% from the prior year.
• Other Working Capital Changes climbed to -$193000.0 in Q1 2026 per EVMN's latest filing, from -$2.4 million in the prior quarter.
• Across five years, Other Working Capital Changes topped out at $4.0 million in Q1 2025 and bottomed at $85000.0 in Q1 2026.
• Historically, Other Working Capital Changes has averaged $1.3 million across 3 years, with a median of $539000.0 in 2024.
• Annual changes were most pronounced in 2025 — Other Working Capital Changes slumped 1092.57% — and 2026, when it increased 6.31%.
• Evommune's Other Working Capital Changes stood at -$202000.0 in 2024, then plunged by 1092.57% to -$2.4 million in 2025, then soared by 91.99% to -$193000.0 in 2026.
• Business Quant data shows EVMN's Other Working Capital Changes at -$193000.0 in Q1 2026, -$2.4 million in Q4 2025, and -$206000.0 in Q1 2025.